Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11479783 | 0.88 | KMT2A (0.67) | RAB9ANPC1KMT2AMEN1ALDH1A1 | |
| SCHEMBL425352 | 0.85 | RAB9A (0.60) | RAB9ANPC1KMT2AMEN1ALDH1A1 | |
| SCHEMBL425351 | 0.85 | SMN1; SMN2 (0.57) | RAB9ANPC1KMT2AMEN1ALDH1A1 | |
| SCHEMBL9851181 | 0.84 | KMT2A (0.58) | RAB9ANPC1KMT2AMEN1ALDH1A1 | |
| SCHEMBL9702275 | 0.83 | MAPK1 (0.62) | RAB9ANPC1KMT2AMEN1ALDH1A1 | |
| SCHEMBL17057207 | 0.83 | KMT2A (0.83) | RAB9ANPC1KMT2AMEN1ALDH1A1 | |
| SCHEMBL11470898 | 0.83 | KMT2A (0.61) | RAB9ANPC1KMT2AMEN1ALDH1A1 | |
| SCHEMBL6359808 | 0.83 | RAB9A (0.60) | RAB9ANPC1KMT2AMEN1ALDH1A1 | |
| SCHEMBL4160352 | 0.83 | MAPK1 (0.55) | RAB9ANPC1KMT2AMEN1ALDH1A1 | |
| SCHEMBL24649557 | 0.81 | KMT2A (0.53) | RAB9ANPC1KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7205434-B2 | Sulphonamido-substituted bridged bicycloalkyl derivatives having a substitute on the bridgehead position; nonpeptidic compounds to treat or prevent Alzheimer's Disease by modulating the processing of amyloid precursor proteins by the putative gamma-secretas to arrest the production of beta-amyloid | MERCK SHARP & DOHME LTD. (GB) | 2007-04-17 | — | — | US | disclosed |
| US-20040186147-A1 | Sulphonamides for control of beta-amyloid production | MERCK SHARP & DOHME LTD. (GB) | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186147-A1 | Sulphonamides for control of beta-amyloid production | APP, APBA1, PSEN2 | RAB9A 2643/4885NPC1 2721/4885KMT2A 4025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.